Detalles de la búsqueda
1.
Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry.
Int J Rheum Dis
; 21(2): 422-430, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29082659
Resultados
1 -
1
de 1
1
Próxima >
>>